Shanghai Junshi Biosciences Co., Ltd. (OTCMKTS:SHJBF) Short Interest Update

Shanghai Junshi Biosciences Co., Ltd. (OTCMKTS:SHJBF) was the target of a significant decline in short interest in July. As of July 31st, there was short interest totaling 188,339 shares, a decline of 73.0% from the July 15th total of 696,739 shares. Based on an average daily trading volume, of 0 shares, the days-to-cover ratio is currently ∞ days.

Shanghai Junshi Biosciences Stock Performance

Shares of Shanghai Junshi Biosciences stock opened at C$3.35 on Thursday. The business has a 50-day moving average of C$3.35 and a 200 day moving average of C$3.17. Shanghai Junshi Biosciences has a 12 month low of C$2.99 and a 12 month high of C$4.23.

Shanghai Junshi Biosciences Company Profile

Shanghai Junshi Biosciences Co, Ltd. is a Shanghai-based biopharmaceutical company dedicated to the research, development and commercialization of monoclonal antibody therapeutics. Since its founding in 2012 as a spin-off from the Shanghai Institute of Pharmaceutical Industry, Junshi has focused on leveraging cutting-edge antibody engineering platforms to develop innovative treatments for oncology, autoimmune conditions, infectious diseases and metabolic disorders. The company’s lead product, toripalimab (Tuoyi), was among the first anti-PD-1 antibodies approved by Chinese regulatory authorities for the treatment of advanced melanoma and nasopharyngeal carcinoma, demonstrating Junshi’s capability to translate research into commercially available immuno-oncology therapies.

Junshi’s pipeline encompasses a diversified portfolio of antibody-based candidates targeting immune checkpoints, cytokines and other disease-associated proteins.